These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34943097)

  • 1. AGEs and sRAGE Variations at Different Timepoints in Patients with Chronic Kidney Disease.
    Molinari P; Caldiroli L; Dozio E; Rigolini R; Giubbilini P; Romanelli MMC; Messa P; Vettoretti S
    Antioxidants (Basel); 2021 Dec; 10(12):. PubMed ID: 34943097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
    Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A
    Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Patients with Chronic Kidney Disease Advanced Glycation End-Products Receptors Isoforms (sRAGE and esRAGE) Are Associated with Malnutrition.
    Caldiroli L; Molinari P; Dozio E; Rigolini R; Giubbilini P; Romanelli MMC; Castellano G; Vettoretti S
    Antioxidants (Basel); 2022 Jun; 11(7):. PubMed ID: 35883745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Advanced Glycation End-Products and Sarcopenia in Patients with Chronic Kidney Disease.
    Molinari P; Caldiroli L; Dozio E; Rigolini R; Giubbilini P; Corsi Romanelli MM; Castellano G; Vettoretti S
    Biomedicines; 2022 Jun; 10(7):. PubMed ID: 35884793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
    Prasad K; Dhar I; Zhou Q; Elmoselhi H; Shoker M; Shoker A
    Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Glycation End Products (AGE) and Soluble Forms of AGE Receptor: Emerging Role as Mortality Risk Factors in CKD.
    Dozio E; Vettoretti S; Caldiroli L; Nerini-Molteni S; Tacchini L; Ambrogi F; Messa P; Corsi Romanelli MM
    Biomedicines; 2020 Dec; 8(12):. PubMed ID: 33371369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
    Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
    Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Autofluorescent Advanced Glycation End Products (AGEs) with Frailty Components in Chronic Kidney Disease (CKD): Data from a Single-Center Cohort Study.
    Molinari P; Caldiroli L; Dozio E; Rigolini R; Giubbilini P; Carminati FMI; Castellano G; Corsi Romanelli MM; Vettoretti S
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM.
    Miranda ER; Fuller KNZ; Perkins RK; Beisswenger PJ; Farabi SS; Quinn L; Haus JM
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.
    Prasad K
    Int J Angiol; 2014 Mar; 23(1):11-6. PubMed ID: 24627612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of EN-RAGE, sRAGE, and its isoforms: cRAGE, esRAGE in obese patients treated by moderate caloric restriction combined with physical activity conducted in hospital condition.
    Kanikowska D; Kanikowska A; Strojny Z; Kawka E; Zawada A; Rutkowski R; Litwinowicz M; Sato M; Grzymisławski M; Bręborowicz A; Witowski J; Korybalska K
    Cytokine; 2024 Aug; 180():156665. PubMed ID: 38823153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
    Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
    J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Receptor for Advanced Glycation End Products and Its Forms in COVID-19 Patients with and without Diabetes Mellitus: A Pilot Study on Their Role as Disease Biomarkers.
    Dozio E; Sitzia C; Pistelli L; Cardani R; Rigolini R; Ranucci M; Corsi Romanelli MM
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Receptor for Advanced Glycation End Products (sRAGE) Isoforms Predict Changes in Resting Energy Expenditure in Adults with Obesity during Weight Loss.
    Popp CJ; Zhou B; Manigrasso MB; Li H; Curran M; Hu L; St-Jules DE; Alemán JO; Vanegas SM; Jay M; Bergman M; Segal E; Sevick MA; Schmidt AM
    Curr Dev Nutr; 2022 May; 6(5):nzac046. PubMed ID: 35542387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Glycation End Products and its Soluble Receptors in the Pathogenesis of Thoracic Aortic Aneurysm.
    Prasad K; Sarkar A; Zafar MA; Shoker A; Moselhi HE; Tranquilli M; Ziganshin BA; Elefteriades JA
    Aorta (Stamford); 2016 Feb; 4(1):1-10. PubMed ID: 27766267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases.
    Steenbeke M; Speeckaert R; Desmedt S; Glorieux G; Delanghe JR; Speeckaert MM
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.
    Romero R; Espinoza J; Hassan S; Gotsch F; Kusanovic JP; Avila C; Erez O; Edwin S; Schmidt AM
    J Perinat Med; 2008; 36(5):388-98. PubMed ID: 18593373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging.
    Scavello F; Zeni F; Tedesco CC; Mensà E; Veglia F; Procopio AD; Bonfigli AR; Olivieri F; Raucci A
    Aging (Albany NY); 2019 Mar; 11(6):1648-1663. PubMed ID: 30903794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings.
    Paradela-Dobarro B; Agra RM; Álvarez L; Varela-Román A; García-Acuña JM; González-Juanatey JR; Álvarez E; García-Seara FJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1050-1060. PubMed ID: 31371263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.